Health

Judge approves $7.25 billion Bayer settlement in Roundup cancer lawsuits

A Missouri judge approved a $7.25 billion settlement resolving tens of thousands of lawsuits claiming Bayer’s Roundup weedkiller caused non-Hodgkin lymphoma.

Bayer, früher Schering, Gebäude in Berlin-Wedding
Berlinschneid / Wikimedia Commons, CC BY-SA 4.0

ST. LOUIS — A Missouri state judge on Friday approved a $7.25 billion settlement between German chemical company Bayer and tens of thousands of plaintiffs who alleged that exposure to the weedkiller Roundup caused their cancer.

Judge Timothy Boyer of a Missouri state court in St. Louis ruled that the agreement was “fair, reasonable and adequate,” according to court filings cited by news reports. The approval marks a major step toward resolving nearly a decade of costly legal battles that have weighed down the company since its purchase of Monsanto in 2018.

The agreement establishes a dedicated fund in which Bayer will deposit up to $7.25 billion over a 21-year period. The resolution applies to existing and prospective claims across the U.S. involving individuals who contracted non-Hodgkin lymphoma, a blood cancer, following Roundup exposure on the job or at home.

Addressing Objections and Payout Details

Under the approved terms, individual claimants are projected to receive payouts averaging between $10,000 and $165,000, DW.com reported. Payout sums will vary based on several criteria, including the applicant’s age, how long they were exposed to the weedkiller, and how severe their cancer is.

Attorneys representing certain cancer patients opposed the deal, arguing that prospective payouts were substantially lower than those received by prior plaintiffs. Boyer rejected those complaints, explaining that postponing approval risked forcing gravely ill victims, including those diagnosed with terminal cancer, to wait “an indeterminate number of years” to receive financial relief.

Christopher Seeger, an attorney representing plaintiffs, lauded the ruling, stating in a public comment that the final approval provides guaranteed financial recovery to cancer sufferers who had waited over ten years for justice, according to news reports.

Bayer CEO Bill Anderson praised the ruling as well, calling final court approval “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.”

Decades of Science and Legal Challenges

Bayer inherited the legal troubles surrounding Roundup when it acquired Monsanto for $63 billion in 2018. Since that acquisition, approximately 200,000 plaintiffs have filed claims against the German enterprise over the product, according to DW.com. While Bayer negotiated a $10.9 billion settlement in 2020 to resolve earlier cases, a separate $1.25 billion deal aimed at resolving future claims failed to receive judicial backing.

The chemical manufacturer has already allocated $16 billion toward Roundup legal expenses, and its stock value has fallen by 46 percent since acquiring Monsanto, DW.com reported.

Bayer has maintained that Roundup and its key active component, glyphosate, are safe and do not cause cancer, pointing to regulatory findings and extensive testing. The U.S. Environmental Protection Agency has concluded glyphosate is unlikely to trigger cancer when used according to instructions, but the World Health Organization’s cancer agency deemed the substance “probably carcinogenic” to humans in 2015.

The court’s approval comes five months after a major 7-2 U.S. Supreme Court ruling in the case of Missouri resident John Durnell. In that decision, the justices determined that federal pesticide law preempted failure-to-warn claims brought under state laws, weakening a core argument long used by plaintiffs.

Although the approved agreement resolves nearly all claims nationwide, Bayer noted that about 200 lawsuits remain active in federal courts, where the company intends to maintain its defense.